Stem Cell Stocks Rise, Led By Athersys Inc. (ATHX, NBS, STEM)
Stem cell stocks (tracked in Tickerspy’s Stem Cell Stock’s Index (*RXSTM) are up over 7% today, led by Athersys Inc (NASDAQ: ATHX). Athersys Inc. rose as high as 395% this morning following news that the company has entered into a…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Stem cell stocks (tracked in Tickerspy’s Stem Cell Stock’s Index (*RXSTM) are up over 7% today, led by Athersys Inc (NASDAQ: ATHX). Athersys Inc. rose as high as 395% this morning following news that the company has entered into a deal with Pfizer (NYSE: PFE) to develop Athersys’s MultiStem, an experimental treatment for inflammatory bowel disease. Athersys recieved an intial payment of $6 million in addition to funding for research. Should the program be successful Athersys will recieved as much as $105 million as well as royalties from sales of the drug should it come to mark.
Other stem cell stocks received a big boost from the news. Neostem Inc. (AMEX: NBS), which operates a operates a center for the collection and storage of stem cell, rose as high as 7.6%. StemCells Inc. (NASDAQ: STEM), which attempts to treat organ disorders with stem cells, climbed as high as 7.2%
Garrett W. McIntyre
Contact [email protected] for any questions or corrections.